PhotoMedex, Inc. announced the appointment of John Koo, MD, as the principal investigator in a clinical study to be carried out for assessing the XTRAC Velocity excimer laser’s efficacy. XTRAC Velocity would be used in the treatment of generalized psoriasis along with Clobex spray.
Dr. Koo, the vice chairman of dermatology at the university of California San Francisco medical center, stated that his associate Tina Bhutani will spearhead the study. Bhutani hopes to find a solution for effectively treating generalized psoriasis, with no internal side effects.
Dennis McGrath, CEO of PhotoMedex, said that the clinical trial would demonstrate that XTRAC Velocity laser treatment would be preferred by psoriasis patients as it is safe and effective. With the new XTRAC treatment protocol, PhotoMedex is anticipating that XTRAC would bring a positive economic effect to health insurers and position the XTRAC as an ideal therapy for severe psoriasis.